Surgery aiming for sub‑mm accuracy

Robotic surgery is moving into work measured in fractions of a millimeter, with companies and hospitals pitching systems that can steady a surgeon’s movements beyond what an unaided hand can do. (fda.gov) In surgery, a millimeter is about the thickness of a credit card edge, and microsurgery often works on blood vessels and lymphatic ducts smaller than that. The United States Food and Drug Administration cleared MMI’s Symani system in April 2024 for work on vessels and ducts from 0.1 to 2.5 millimeters in open breast, extremity, and lymphatic procedures. (fda.gov) These systems do not operate on their own. A surgeon sits at a console or hand controls, and the robot scales down motion, filters hand tremor, and moves tiny wristed instruments inside a field where a slip can damage a vessel wall or miss a stitch. (mmimicro.com; sciencedirect.com) Companies are leaning on precision claims as they try to expand beyond standard robotic surgery into microsurgery, where the targets are smaller and the procedures can last for hours. THINK Surgical says its TMINI orthopedic platform delivers “sub-millimeter and sub-degree accuracy,” while MMI says Symani is built for microsurgery and supermicrosurgery with the smallest wristed instruments in its class. (thinksurgical.com; mmimicro.com) Hospitals are now using that pitch in patient care. Tampa General Hospital and the University of South Florida said in December 2025 that Dr. Nicholas Panetta performed the first fully robotic lymphaticovenous bypass in the United States with the Symani system, calling sub-millimeter precision essential for lymphedema surgery. (usf.edu) The fatigue argument is central to the sales case because microsurgery can mean hours bent over a microscope, repeating hand motions on structures barely wider than a human hair. A 2025 review chapter on the MicroSure MUSA robot said robotic platforms can filter tremor, scale motion, and mitigate fatigue, and a 2025 ergonomics study tracked 85 consecutive robot-assisted microsurgical operations during one hospital’s rollout. (sciencedirect.com; pubmed.ncbi.nlm.nih.gov) That does not mean the machines erase risk. The Food and Drug Administration’s Manufacturer and User Facility Device Experience database continues to collect reports of robotic surgery malfunctions and adverse events, and a 2025 review of da Vinci reports from 2015 through June 2025 said large-scale device-safety evaluation is still limited. (fda.gov; link.springer.com) The evidence base is also still being built procedure by procedure. MMI said in October 2025 that it enrolled the first patient in its PRECISE United States study, and ClinicalTrials.gov lists a separate prospective Symani investigation that began on January 20, 2026, with estimated enrollment of 180 patients. (mmimicro.com; clinicaltrials.gov) Researchers and companies are pushing even further, including systems aimed at movements smaller than a human hand can reliably reproduce and devices designed for sub-millimeter spaces inside the body. Nature reported in 2025 that surgical robots under development can hold steady at submicron scales, while a 2024 Nature Communications paper described a fiberscopic robot built for sub-millimeter maneuvering, imaging, and treatment. (nature.com; nature.com) For now, the near-term story is narrower than the marketing: surgeon-controlled robots are moving into operations on 0.1-to-2.5-millimeter structures, and hospitals are testing whether steadier tools and less fatigue translate into better results in the operating room. (fda.gov; clinicaltrials.gov)